Bombay High Court observed that restraining Serum Institute from using Covishield name would disrupt the Covid-19 vaccination programme in the case of Cutis Biotech v. Serum Institute of India. This Connect highlights the reasoning given by the court in holding that it is not a case of ‘passing off’.